Skip to content

Lumbal Erector Spinae Plane Block for Pain Management After Total Hip Arthroplasty

Ultrasound-Guided Lumbal Erector Spinae Plane Block on Postoperative Pain Management After Total Hip Arthroplasty

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07240961
Enrollment
60
Registered
2025-11-21
Start date
2025-11-01
Completion date
2026-07-07
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty (THA)

Keywords

hip arthroplasty, Lumbal Erector Spinae Plane Block, pain managment

Brief summary

The Erector Spinae Plane (ESP) block or spinal erector block was first described in September 2016 by a Canadian team. It's a block that was initially used for the treatment of chronic thoracic neuropathic pain. The ESP block is one of the inter-fascicular blocks and it's an easy-to-perform technique.In the literature, it has been reported that Lumbar ESPB provides effective analgesia after a hip surgery. The purpose of this prospective randomized study was to compare the analgesic effects of the ultrasound-guided lumbar Erector Spinae Plane block on postoperative pain management versus the multimodal analgesia after total hip arthroplasty.

Detailed description

Patients aged more than 18 years, ASA I-III scheduled for primary total hip arthroplasty with lateral approach and under general anesthesia Patients were randomly assigned, into 1 of 2 groups, namely, group ESPBL and group Placebo, using sealed envelopes * For ESPBL group: Lumbar ESP block performed after anesthesia induction. A low-frequency ultrasound probe will be placed longitudinally 2-3 cm lateral to the L4 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and following confirmation of the correct position of the needle, between the erectorspinae muscle and the transverse process,30 ml of local anesthetic (0.25% bupivacaine/0.2% ropivacaine) will be administered for the block. * For Placebo group: patients had multimodal analgesia without lumbar ESP block Patients will be transferred to continuous care unit for 24 hours. Post-operative analgesia will include: 1. Paracetamol 1g IV every 8 hours for 1 day then oral paracetamol 1g every 8 hours for 4 weeks. 2. Diclofenac sodium(50mg) 1 tablet x 2 per day for 5 days. 3. PCA morphine (Patient Controlled Analgesia), as a rescue analgesia, programmed as: Bolus of 1mg/ refractory period of 10 min/ maximum dose set up at 10mg every 12h. The primary outcome of the study is to compare postoperative opioids consumption in the first 24 postoperative hours. Secondary endpoints: Secondary outcomes are: intraoperative opioid consumption, postoperative pain scores, sitting position and adverse effects related to opioids.

Interventions

PROCEDURELumbal Erector Spinae Plane Block

Lumbar ESP block performed after anesthesia induction. A low-frequency ultrasound probe will be placed longitudinally 2-3 cm lateral to the L4 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and following confirmation of the correct position of the needle, between the erectorspinae muscle and the transverse process,30 ml of local anesthetic (0.25% bupivacaine/0.2% ropivacaine) will be administered for the block.

PROCEDUREintravenous pain killers

intravenous pain killers

Sponsors

University Tunis El Manar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* primary total hip arthroplasty with lateral approach and under general anesthesia .

Exclusion criteria

* • Contraindication or refusal to regional anesthesia * Contraindication to non-steroidal anti-inflammatory (NSAID's) * Allergy to opioids * Allergy to paracetamol * Creatinine clearance \< 30ml/min * Weight\<50 kg or \>100kg * Psychiatric disorders and difficulty of communication * Lower limb neurological deficit * Patients undergoing bilateral or revision total hip replacement

Design outcomes

Primary

MeasureTime frameDescription
morphine consumptionDay 1total morphine dose

Secondary

MeasureTime frameDescription
pain during walkDay 7numerical pain rating scale \[1 to 10 worse outcome\]
pain scoresHour 2, Hour 4, Hour 6, Hour 12, Hour 18, Hour 24 and on Day 2 and Day 7.numerical pain rating scale \[1 to 10 worse outcome\]
ROMDay 1Range of mouvement \[0° to 90°best outcome\]
pain on sitting positionDay 1numerical pain rating scale \[1 to 10 worse outcome\]
QR 9 scoreDay 2quality of recovery score \[0 to 18 best outcome\]
intraoperative opioid consumptionend of surgerytotal fentanyl dose

Countries

Tunisia

Contacts

Primary ContactKAABACHI OLFA

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026